Patents by Inventor Elise CHIFFOLEAU

Elise CHIFFOLEAU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20230331852
    Abstract: The invention pertains to the field of immunotherapy. The present invention provides new specific anti-CLEC-1A compounds, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The use of the compounds of the invention may be useful for treating deleterious conditions.
    Type: Application
    Filed: December 4, 2020
    Publication date: October 19, 2023
    Inventors: Elise CHIFFOLEAU, Nicolas POIRIER, Ariane DESSELLE, Virginie THEPENIER, Caroline MARY, Vanessa GAUTTIER, Sabrina PENGAM
  • METHODS FOR PROMOTING T CELLS RESPONSE
    Publication number: 20220281983
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: September 8, 2022
    Inventors: Elise CHIFFOLEAU, Geraldine TEPPAZ, Nicolas POIRIER, Bernard VANHOVE, Vanessa GAUTTIER
  • Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)
    Patent number: 11365257
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICS
    Inventors: Elise Chiffoleau, Géraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
  • METHODS FOR PROMOTING T CELLS RESPONSE
    Publication number: 20190309075
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Application
    Filed: October 20, 2017
    Publication date: October 10, 2019
    Inventors: Elise CHIFFOLEAU, Géraldine TEPPAZ, Nicolas POIRIER, Bernard VANHOVE, Vanessa GAUTTIER